Mounjaro vs Zepbound — Comparison & Availability

MounjaroZepbound
Brand NameMounjaroZepbound
Generic Nametirzepatidetirzepatide
Drug ClassGIP/GLP-1 receptor agonistGIP/GLP-1 receptor agonist
Findability Score13/10014/100
FindabilityVery DifficultVery Difficult
Avg Pharmacy Calls~26~26

Which Is Easier to Find Right Now?

Zepbound is currently easier to find with a Findability Score of 14/100 (Very Difficult), compared to Mounjaro at 13/100 (Very Difficult).

On average, you'll need to call about 26 pharmacies to find Zepbound, versus 26 pharmacies for Mounjaro. If you're having trouble finding either, FindUrMeds can search for you.

Key Differences Between Mounjaro and Zepbound

Both Mounjaro (tirzepatide) and Zepbound (tirzepatide) belong to the GIP/GLP-1 receptor agonist drug class. While they share a similar mechanism of action, they may differ in dosing schedules, side effect profiles, and how individual patients respond to each. Your doctor can help determine which is the better fit based on your specific needs.

Frequently Asked Questions

Is Mounjaro or Zepbound easier to find?

Based on current availability data, Zepbound has a Findability Score of 14/100 compared to Mounjaro's 13/100. Zepbound typically requires about 26 pharmacy calls to locate, while Mounjaro may take around 26 calls.

Can I switch from Mounjaro to Zepbound?

Switching between Mounjaro and Zepbound requires a conversation with your prescribing doctor. They can evaluate whether the switch is appropriate based on your medical history, current condition, and how you've responded to your current medication. Never switch medications without medical guidance.

Which is cheaper, Mounjaro or Zepbound?

Prices vary by pharmacy, insurance coverage, and whether a generic is available. Mounjaro (generic: tirzepatide) and Zepbound (generic: tirzepatide) may have different out-of-pocket costs depending on your plan. Using GoodRx coupons or asking your pharmacist about generic alternatives can help reduce costs for either medication.

Summarize this article with AI:

Learn More